U.S. Biotech Stock News

Wave Life Sciences recently received board approval to redomicile its parent company from Singapore to a new Delaware-based entity via a one-for-one share exchange, aiming to cut regulatory burdens and compliance costs, with completion targeted by mid-2026 subject to shareholder and Singapore High Court approvals. This shift to a US domicile could meaningfully reshape Wave’s corporate, tax, and regulatory framework, potentially influencing how it executes its RNA-focused business...

Open Text (NasdaqGS:OTEX) just highlighted its European focus, rolling out data and AI offerings on the AWS European Sovereign Cloud and teaming up with S3NS in France, while refreshing client-facing leadership roles. See our latest analysis for Open Text. These European cloud and data-sovereignty moves arrive after a 7 day share price return of 5.89% and a 30 day gain of 3.50%. However, they sit against a 26.40% year to date decline and a 5 year total shareholder return of 43.47% in the red,...

Septerna, Inc. recently began dosing healthy volunteers in a randomized, placebo-controlled Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, using single-ascending and multiple-ascending dose designs to assess safety, tolerability, pharmacokinetics and pharmacodynamics. This first-in-human study, which could enroll up to 150 participants and tracks biomarkers such as endogenous PTH and serum calcium, marks a key progression of Septerna’s GPCR-targeted pipeline into...

California Water Service Group (CWT) has attracted fresh attention after recent share price moves, with the stock showing gains over the past week, month, and past 3 months relative to its last close of $46.85. See our latest analysis for California Water Service Group. That recent 4.2% 1 day share price return and 6.7% 30 day share price return sit against a 1 year total shareholder return decline of 5.2%. This suggests short term momentum is improving while longer term returns remain under...

Incyte has reported positive Phase 3 results for tafasitamab (Monjuvi/Minjuvi) in first-line diffuse large B-cell lymphoma, with full data to be presented at the 2026 ASCO Annual Meeting, supporting global regulatory submissions, and separately entered a clinical collaboration with Adagene to test a novel combination therapy in microsatellite stable colorectal cancer in a Phase 1 trial planned for 2026. These advances highlight Incyte’s effort to broaden its oncology portfolio beyond...

Over the last 7 days, the United States market has risen by 3.6%, and over the past year, it has seen a remarkable increase of 39%, with earnings forecasted to grow by 16% annually. In such a thriving environment, identifying stocks that are potentially undervalued can offer opportunities for investors looking to capitalize on discrepancies between current prices and estimated worth.

Context for Vertex Pharmaceuticals after recent share performance Vertex Pharmaceuticals (VRTX) has recently seen its share price under pressure, with a 3.3% decline over the past month and an 8.0% negative total return over the past year. This performance has prompted closer attention from investors. See our latest analysis for Vertex Pharmaceuticals. With the share price at US$439.18 and a 1 year total shareholder return of 8.0% in the red, but a 5 year total shareholder return of 102.4%,...

In recent weeks, CoStar Group’s Homes.com platform released a March report spotlighting the priciest publicly marketed home sales across major U.S. metros, led by a US$170 million Miami estate, with Los Angeles and New York City also registering ultra-luxury transactions. At the same time, hedge fund Third Point publicly exited its CoStar position after criticizing ongoing investment in Homes.com, highlighting growing debate over how the residential push fits within CoStar’s broader business...

Marriott International’s Luxury Collection is partnering with designer Margherita Maccapani Missoni on an immersive Milan Design Week pop-up and capsule fashion collection at Casa Brera, while also advancing its Autograph Collection footprint with the NUMAJ hotel in Saudi Arabia’s AlUla and opening the Noormahal Palace Hotel in Karnal, India. Together, these moves highlight Marriott’s push to deepen its luxury positioning by blending high-end hospitality with fashion-led experiences and...

Aon (NYSE:AON) is back in focus after expanding its Data Center Lifecycle Insurance Program by an additional $1 billion, lifting total capacity to $3.5 billion and extending coverage to existing post-commissioning data centers. See our latest analysis for Aon. Aon’s recent product and dividend announcements come after a mixed period for investors, with the share price at $331.95 and a 30 day share price return of 1.94%, against a year to date share price decline of 3.58% and a 1 year total...

The United States market has shown robust performance, climbing 3.6% in the last week and 39% over the past year, with earnings projected to grow by 16% annually. In this thriving environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and strategic direction.

Over the last 7 days, the United States market has risen 3.6%, and over the past year, it has climbed 39%, with earnings expected to grow by 16% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for investors seeking growth at lower price points. By focusing on those with strong balance sheets and solid fundamentals, these stocks can present an underappreciated chance for stability and potential upside in today's market conditions.

In the past week, Griffon reported quarterly results with revenues and adjusted operating income coming in ahead of analyst expectations, even as full-year revenue guidance fell short of consensus and lagged peers. The contrast between a stronger-than-expected quarter and relatively soft guidance has sharpened attention on how much of Griffon’s recent strength is sustainable versus cyclical. With Griffon’s recent revenue beat but softer full-year outlook, we’ll examine how this mixed...

Recent performance snapshot Zurn Elkay Water Solutions (ZWS) has attracted investor attention following a period in which the stock posted a modest one-day move, weaker performance over the past week, and positive returns over the past month and past three months. See our latest analysis for Zurn Elkay Water Solutions. At a share price of $47.78, Zurn Elkay Water Solutions has recently paired a weaker 7 day share price return with a stronger 1 month share price return, while its 1 year total...

10x Genomics has launched Atera, an in situ spatial biology platform offering whole-transcriptome, single-cell–sensitivity analysis at scale across fresh-frozen and FFPE tissues, with pre-orders open and shipments targeted for the second half of 2026. Early Atera data from leading groups like the June Lab and the German Cancer Research Center suggest the platform can reveal previously hidden tumor–immune interactions that may reshape research and drug discovery approaches. We’ll now examine...

Under Armour (UAA) is back in the spotlight after Unrivaled Sports announced new partnerships with the brand and DICK'S Sporting Goods, focused on youth sports programming nationwide and exclusive apparel roles at marquee events. See our latest analysis for Under Armour. Investors have seen momentum build recently, with a 7 day share price return of 7.65% and a 30 day share price return of 12.99%. At the same time, the 1 year total shareholder return of 15.16% contrasts with a 5 year total...

Donnelley Financial Solutions (DFIN) drew renewed attention to its stock after authorizing a new share repurchase program of up to $150 million, running through December 31, 2027, alongside updates on recent buyback activity. See our latest analysis for Donnelley Financial Solutions. The buyback announcement and recent repurchases come at a time when the share price is US$52.53, with a 7 day share price return of 7.40% and a 30 day share price return of 13.02%. The 1 year total shareholder...

MACOM Technology Solutions Holdings (MTSI) has drawn fresh attention after introducing 448G PAM4 modulator drivers designed for 1.6T and 3.2T optical transceivers, directly tying the business to high speed AI data center networking. See our latest analysis for MACOM Technology Solutions Holdings. The recent 448G PAM4 launch comes as momentum in MACOM's share price has been strong, with a 60.65% year to date share price return and a very large 1 year total shareholder return. This indicates...

Morgan Stanley recently elevated Affirm Holdings to its Top Pick list, arguing that concerns around private credit are too pessimistic and pointing to upcoming company updates on gross merchandise volume, margins, and long-term earnings targets at its May Investor Forum as important reference points. An interesting angle is Morgan Stanley’s expectation that Affirm will outline a fiscal 2028 GAAP EPS range that the bank views as conservative, potentially reframing how investors think about...

The United States market has experienced a notable upswing, climbing 3.6% over the last week and an impressive 39% over the past year, with earnings projected to grow by 16% annually. In such a dynamic environment, identifying stocks that are not only poised for growth but also remain under the radar can offer unique opportunities for investors seeking to capitalize on market momentum while discovering potential value.

Event overview and recent stock performance Ladder Capital (LADR) has attracted fresh attention after recent share moves, with the stock showing a 5.3% gain over the past month but a 7% decline over the past 3 months. See our latest analysis for Ladder Capital. Zooming out, Ladder Capital’s share price return has softened year to date, with a 7.3% decline. However, the 1 year total shareholder return of 12.2% and 3 year total shareholder return of 44.2% indicate a constructive longer term...

What recent performance says about East West Bancorp East West Bancorp (EWBC) has drawn attention after a strong month, with the stock showing a 15% return and a gain of about 6% over the past 3 months. This recent performance has prompted some investors to reassess its valuation. See our latest analysis for East West Bancorp. Putting that move in context, the 15.0% 1 month share price return sits alongside a 3.5% year to date share price return and a 60.2% 1 year total shareholder return...

Setting the scene on Cboe Global Markets (CBOE) Cboe Global Markets (CBOE) has drawn fresh attention after the stock’s recent move, with investors weighing its current valuation against trading performance across options, equities, futures, and FX platforms. With a last close of $304.40 and a market cap of about $31.4b, Cboe’s recent returns over the past month and past 3 months are prompting closer scrutiny of how its diverse revenue streams support that pricing. See our latest analysis for...

Broadcom (AVGO) is back in focus after reports that Google may add Marvell as a custom AI chip partner, raising questions about how competition and supplier diversification could influence the stock’s recent strong run. See our latest analysis for Broadcom. The latest 1 day share price decline of 1.70% to US$399.63 comes after reports of Google talking to Marvell, but that pullback sits against a 30 day share price return of 28.70% and a very strong 1 year total shareholder return of 142.39%,...